MTTlab & Vivomicx announce collaboration to make preclinical drug discovery and drug development more efficient.
Trieste, Italy and Groningen, The Netherlands (September 2017)
MTTlab Srl and Vivomicx BV today announce their collaboration to make the trajectory of preclinical drug discovery & development more efficient by providing more in-depth information from the preclinical tissue samples. The collaboration covers joint marketing and joint execution of preclinical testing combining the expertise of both companies.
MTTlab delivers both in vitro and in vivo data sets for the preclinical evaluation of an investigational compound which can be used for regulatory submissions, project evaluation, scientific publications and fundraising. MTTlab provides support for our clients’ studies or projects from the earliest stages and assists with both scientific and regulatory challenges to obtain valid results within requested deadlines.
For more information about MTTlab, please contact Martin Mojzisek.
Vivomicx has developed validated protocols to analyze preclinical or clinical tissue samples using Laser Dissection Microscopy in combination with Quantitative RT-PCR analysis. This allows the in-depth analysis of gene activity in subsets of cells in the complexity of the in vivo tissue. Using this technology we can assess gene expression profiles and therefore the molecular identity of cells; e.g. is your target molecule expressed in the cells of interest in diseased tissue? On top of that we can determine the true effects of a drug on mRNA expression levels in the cells of interest; e.g. what is the effect of your drug in terms of target inhibition and/or downstream effector modulation.
For more information about Vivomicx, please contact Jan Zuidema.